Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Blincyto in relapsed/refractory B-cell leukemia or lymphoma
NCT03605589Phase 1Withdrawn
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Dose Limiting Toxicities at 70 days and Treatment related toxicities at 70 days. Planned start Sep 2018; status: withdrawn.
02
Drugs
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT03605589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605589.